<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849754</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01795-34</org_study_id>
    <nct_id>NCT04849754</nct_id>
  </id_info>
  <brief_title>Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy</brief_title>
  <acronym>QUANTI-SUV</acronym>
  <official_title>Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy for the Follow-up of Patients With Transthyretin Amyloidosis Treated With Tafamidis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l'Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GCS Ramsay Santé pour l'Enseignement et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant&#xD;
      reduction in mortality. The Perugini score is commonly used on planar bone scans to&#xD;
      differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate&#xD;
      amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested&#xD;
      to evaluate the amyloid burden, there a need for quantitative methods for longitudinal&#xD;
      assessment of the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac amyloidosis is a cause of restrictive cardiomyopathy with preserved ejection fraction&#xD;
      associated with amyloid fibrils deposits in the myocardium. Two types of amyloid commonly&#xD;
      infiltrate the heart: immunoglobulin light-chain amyloid (AL), and transthyretin-related&#xD;
      amyloid amyloidosis (ATTR). Cardiac imaging is currently used for the diagnosis of ATTR,&#xD;
      including planar scintigraphy with bone seeking radiopharmaceuticals, cardiac magnetic&#xD;
      resonance and echocardiography with global longitudinal strain assessment.Although&#xD;
      semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need&#xD;
      for quantitative methods for longitudinal assessment of the disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of SUVmax by quantitative analysis by bisphosphonate scintigraphy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Patients with transthyretin related cardiac amyloidosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bone scintigraphy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>bone scintigraphy</intervention_name>
    <description>Bone scintigraphy</description>
    <arm_group_label>Patients with transthyretin related cardiac amyloidosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, male or female, over 18 years of age&#xD;
&#xD;
          -  Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy&#xD;
&#xD;
          -  Patient with signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with systemic AL amyloidosis&#xD;
&#xD;
          -  Protected patient : major under guardianship, tutorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredric MOUQUET</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Le Bois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic MOUQUET</last_name>
    <phone>0642377375</phone>
    <email>fmouquet@ovh.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital privé Le Bois</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Mouquet</last_name>
      <phone>0642377375</phone>
      <email>fmouquet@ovh.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

